Atreca, Inc. announced a corporate reorganization to reduce expenses and extend its cash runway. As part of the reorganization, Atreca will be undertaking cost-saving measures, including suspending development of ATRC-101 and reducing its workforce by approximately 40%. Going forward operations will focus on advancing current preclinical antibody-drug conjugate (ADC) candidates, including APN-497444, while preserving core discovery capabilities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 USD | -6.43% | +3.90% | -39.39% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.39% | 3.17M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BCEL Stock
- News Atreca, Inc.
- Atreca, Inc. Reduces its Workforce by Approximately 40%